Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.76 and traded as low as $2.86. Galmed Pharmaceuticals shares last traded at $2.93, with a volume of 48,546 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of Galmed Pharmaceuticals in a report on Wednesday, October 9th. They issued a “sell” rating on the stock.
View Our Latest Research Report on GLMD
Galmed Pharmaceuticals Stock Performance
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Recommended Stories
- Five stocks we like better than Galmed Pharmaceuticals
- What Are Dividends? Buy the Best Dividend Stocks
- MP Materials: Rare Earth Elements Powering the EV Boom
- What Does Downgrade Mean in Investing?
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- The 3 Best Retail Stocks to Shop for in August
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
